Loading...
Loading...
IVVD| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.5M |
| Gross Profit | -0.5M |
| Operating Expense | 53.7M |
| Operating I/L | -53.9M |
| Other Income/Expense | 3.6M |
| Interest Income | 3.6M |
| Pretax | -50.2M |
| Income Tax Expense | -0.4M |
| Net Income/Loss | -50.2M |
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in antibody-based solutions for infectious diseases. Their lead product candidate, ADG20, is a neutralizing antibody in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. The company generates revenue through the discovery, development, and commercialization of proprietary antibodies, as well as through collaboration agreements with research institutions for the identification of vaccine candidates for influenza and beta coronaviruses.
